GlassScriptPhysician profile
Anna Maria B Toker
NPI 1245209535
$5,067.39
in general payments reported to CMS, 2019-2025
32 companies · $58.29 in 2025
The $58.29 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $3,565 · 2021: $333 · 2022: $458 · 2023: $28.87 · 2024: $71.16 · 2025: $58.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $3,175.73 | 2020 | |
| Merz North America, INC. | $338.67 | 2020-2022 | |
| Zyla Life Sciences, INC. | $272.05 | 2019-2020 | |
| Axonics, INC. | $190.51 | 2020-2022 | |
| Stryker Corporation | $161.07 | 2020 | |
| Braintree Laboratories, INC. | $131.58 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.60 | 2021-2024 | Xifaxan |
| Intuitive Surgical, INC. | $92.55 | 2020 | |
| Tela Bio, INC. | $54.58 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $52.95 | 2021 | |
| Heron Therapeutics, INC. | $43.73 | 2022 | |
| Astellas Pharma US INC | $41.24 | 2019 | |
| Smith+Nephew, INC. | $39.62 | 2019-2021 | |
| Thd America, INC. | $37.71 | 2025 | |
| Laborie Medical Technologies Corp. | $36.39 | 2024 | Renovarp |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.73 | 2021 | |
| Amag Pharmaceuticals, INC. | $24.50 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $21.57 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $21.30 | 2019 | |
| Baxter Healthcare | $20.87 | 2021 | |
| Coloplast Corp | $20.60 | 2022 | |
| Shire North American Group INC | $19.70 | 2019 | |
| Pfizer INC. | $19.59 | 2020 | |
| Exeltis, USA INC. | $18.34 | 2024 | Slynd |
| Merck Sharp & Dohme LLC | $17.17 | 2020 | |
| Endo Pharmaceuticals INC. | $15.95 | 2019 | |
| Cook Medical LLC | $15.54 | 2019 | |
| Therapeuticsmd, INC. | $13.02 | 2019 | |
| Kerecis Limited | $12.91 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $12.01 | 2021 | |
| Mallinckrodt Enterprises LLC | $11.82 | 2019 | |
| Levita Magnetics International Corp | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Maria Toker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.